Breakthrough in HIV Management: Insights from the Lancet-Published ARTISTRY-1 Trial

The recent publication in The Lancet has sparked significant interest in the global health community, particularly in regions like India where HIV remains a persistent challenge. The phase 3 ARTISTRY-1 trial demonstrates that a novel single-tablet regimen combining bictegravir (BIC) and lenacapavir (LEN)—two potent antiretroviral drugs—successfully maintains viral suppression in people living with HIV (PLHIV) who were previously on complex, multi-tablet regimens. This finding, detailed in a randomized, open-label study led by Professor Chloe Orkin from Queen Mary University of London, offers hope for simplifying treatment and improving adherence.

Participants in the trial, many of whom had been managing HIV for nearly three decades with an average of three pills per day, showed remarkable outcomes. Nearly 96% achieved or maintained HIV-1 RNA levels below 50 copies per milliliter after 48 weeks, comparable to those continuing their prior therapies. This non-inferiority result, achieved without emergent drug resistance, highlights the regimen's potential as a game-changer for long-term HIV care.

Understanding the ARTISTRY-1 Trial Design and Demographics

Conducted across 90 sites in 15 countries, the ARTISTRY-1 trial (NCT05502341) enrolled 557 virologically suppressed adults aged 18 and older on complex antiretroviral therapy (ART) for at least six months. Complex regimens were defined as those including boosted protease inhibitors (PIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs) plus additional agents, totaling at least two pills daily or involving injectables.

The study population reflected real-world complexities: median age of 60 years, 18% women, 81% with prior resistance history, and over half managing multiple comorbidities like dyslipidemia (68%) and hypertension (50%). Randomization was 2:1 to BIC/LEN (with initial loading doses) versus staying on current therapy. Efficacy was assessed using the FDA snapshot analysis at week 48, confirming non-inferiority with a margin of 4%.

• Virological success (HIV-1 RNA <50 copies/mL): 96% (BIC/LEN) vs. 94% (complex regimens)
• CD4 cell count changes: Stable or improved (+18 cells/μL median)
• No treatment-emergent resistance in failures

Safety profiles were comparable, with adverse events mostly mild and discontinuations low (2% vs. 1%). Notably, BIC/LEN improved lipid profiles, addressing a common concern in aging PLHIV.

Evolution of HIV Treatment: From Multi-Pill to Single-Tablet Regimens

Antiretroviral therapy has transformed HIV from a fatal disease to a manageable chronic condition since the introduction of highly active ART (HAART) in the mid-1990s. Early regimens required up to 20+ pills daily, fraught with toxicity and poor adherence. Advances led to fixed-dose combinations, culminating in single-tablet regimens (STRs) like Biktarvy (BIC/emtricitabine/tenofovir alafenamide).

However, resistance, drug interactions, and comorbidities limit STR use for ~10-20% of PLHIV globally. BIC, an integrase strand transfer inhibitor (INSTI), and LEN, a first-in-class capsid inhibitor, target different HIV lifecycle stages, offering high barrier to resistance. Their combination as an STR targets this underserved group, potentially broadening access.

HIV Landscape in India: Burden and Current Treatment Paradigms

India harbors the third-largest HIV epidemic, with National AIDS Control Organization (NACO) estimating ~2.6 million PLHIV as of recent 2025 reports, and ~1.8 million on ART under the 'test-and-treat' strategy launched in 2017. First-line therapy is predominantly the single-tablet Tenofovir/Lamivudine/Dolutegravir (TLD), rolled out since 2020, simplifying care for most.

Yet, approximately 4-5% (~70,000-90,000) are on second-line regimens due to virological failure, with even fewer on third-line. These advanced lines often involve boosted PIs like atazanavir/ritonavir plus nucleoside reverse transcriptase inhibitors (NRTIs), requiring multiple daily doses and monitoring for side effects like renal toxicity and dyslipidemia.

Prevalence is highest in high-risk groups: female sex workers, men who have sex with men (MSM), people who inject drugs (PWID), and transgender persons, concentrated in states like Maharashtra, Andhra Pradesh, and Mizoram.

Adherence Challenges with Complex Regimens in the Indian Context

Adherence to ART exceeds 95% is crucial for viral suppression and preventing resistance. Complex regimens exacerbate non-adherence due to pill burden, food restrictions, adverse effects, stigma, and socioeconomic barriers prevalent in India.

• High pill count: Increases forgetfulness, especially among illiterate or migrant workers
• Side effects: Nausea, diarrhea from PIs deter compliance
• Socioeconomic: Cost (though free via NACO, generics needed), travel to ART centers
• Psychosocial: Depression, alcohol use, discrimination

Studies show suboptimal adherence rates of 20-30% in second/third-line patients, risking treatment failure and transmission. A simplified STR like BIC/LEN could mitigate these, enhancing quality of life and public health outcomes.

Expert Perspectives and the Need for India-Specific Validation

Dr. I.S. Gilada, President-Emeritus of the AIDS Society of India, welcomes the findings but stresses India-specific phase 3 trials, costing ~Rs 10 crore, to account for genetic diversity, co-infections like TB, and pharmacogenomics. Indian generics could then produce affordable versions, as with TLD.

While BIC/LEN remains investigational globally, lenacapavir's long-acting injectable form is approved for PrEP in some regions. Gilead plans regulatory submissions post-trial data.

Implications for Research in Indian Higher Education Institutions

This study exemplifies university-driven innovation, with contributors from institutions like Queen Mary University of London and University of the Witwatersrand. Indian universities such as AIIMS, PGIMER, and IITs could lead localized trials, fostering pharmacology, epidemiology, and clinical research.

Opportunities abound for PhD/postdoc positions in HIV virology and drug development. Platforms like Rate My Professor highlight experts mentoring in infectious diseases. Collaborative global trials enhance NIRF rankings and attract funding via ICMR/NACO.

Potential Impacts and Future Outlook for HIV Care in India

Adopting BIC/LEN could reduce virological failure rates, lower transmission (U=U principle), and cut healthcare costs by minimizing hospitalizations. NACO's NACP-V aims for 95-95-95 targets by 2025; simplified regimens support this.

• Improved adherence: Single pill vs. 3+ daily
• Patient satisfaction: Trial showed +7 point increase
• Comorbidity management: Better lipids, renal safety
• Equity: Generics make accessible to 1.8M on ART

Challenges include regulatory approval, supply chains, and training. Long-term data from ongoing extensions will clarify durability.

Actionable Insights for Researchers, Clinicians, and Policymakers

Clinicians should monitor patients on second/third-line for adherence using tools like viral load testing. Researchers can explore pharmacogenomics of BIC/LEN in Indian populations. Policymakers: Prioritize trials via DBT/ICMR funding.

For aspiring academics, explore career advice on building HIV research profiles. Institutions can partner internationally, as seen in past Lancet India studies on vertical transmission.

Photo by Annie Spratt on Unsplash

Conclusion: A Step Toward Simplified, Equitable HIV Control

The Lancet study heralds a new era for HIV management, particularly resonant for India's diverse patient needs. By simplifying regimens, it promises better outcomes and research synergies. Explore opportunities at Higher Ed Jobs, review faculty via Rate My Professor, or seek career advice in public health. University jobs in virology await—browse now. For employers, post a job to attract top talent.